233 related articles for article (PubMed ID: 34244706)
1. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Pina Vegas L; Le Corvoisier P; Penso L; Paul M; Sbidian E; Claudepierre P
Rheumatology (Oxford); 2022 Apr; 61(4):1589-1599. PubMed ID: 34244706
[TBL] [Abstract][Full Text] [Related]
2. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
3. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
Pina Vegas L; Penso L; Claudepierre P; Sbidian E
JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
[TBL] [Abstract][Full Text] [Related]
4. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
[TBL] [Abstract][Full Text] [Related]
5. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
6. The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids.
Persson R; Hagberg KW; Qian Y; Vasilakis-Scaramozza C; Jick S
Rheumatology (Oxford); 2021 Apr; 60(4):1926-1931. PubMed ID: 33159794
[TBL] [Abstract][Full Text] [Related]
7. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
Vasilakis-Scaramozza C; Persson R; Hagberg KW; Jick S
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1755-1763. PubMed ID: 31981426
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
Wu JJ; Pelletier C; Ung B; Tian M
Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
[No Abstract] [Full Text] [Related]
10. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E
JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624
[TBL] [Abstract][Full Text] [Related]
11. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
Pina Vegas L; Claudepierre P; Sbidian E
Rheumatology (Oxford); 2022 Oct; 61(10):e321-e322. PubMed ID: 35686890
[No Abstract] [Full Text] [Related]
12. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
Pina Vegas L; Claudepierre P; Sbidian E
Rheumatology (Oxford); 2022 Aug; 61(8):e238-e239. PubMed ID: 35333297
[No Abstract] [Full Text] [Related]
13. Apremilast and its role in psoriatic arthritis.
Sandhu VK; Eder L; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
[TBL] [Abstract][Full Text] [Related]
14. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Ouyang F
Rheumatology (Oxford); 2022 Oct; 61(10):e320. PubMed ID: 35686859
[No Abstract] [Full Text] [Related]
15. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Suruki RY; Desai RJ; Davis KJ; Berlin JA; Gagne JJ
Rheumatology (Oxford); 2022 Aug; 61(8):e236-e237. PubMed ID: 35333307
[No Abstract] [Full Text] [Related]
16. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.
Seror R; Lafourcade A; De Rycke Y; Pinto S; Castaneda J; Fautrel B; Mariette X; Tubach F
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35738803
[TBL] [Abstract][Full Text] [Related]
17. Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in Korea.
Cho H; Kim YJ; Moon IJ; Lee WJ; Won CH; Lee MW; Chang SE; Jung JM
J Dermatolog Treat; 2024 Dec; 35(1):2321194. PubMed ID: 38403279
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
[TBL] [Abstract][Full Text] [Related]
19. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
20. Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database.
Pina Vegas L; Sbidian E; Penso L; Claudepierre P
Rheumatology (Oxford); 2021 Mar; 60(3):1243-1251. PubMed ID: 32911531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]